Profile data is unavailable for this security.
About the company
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
- Revenue in USD (TTM)9.68m
- Net income in USD-222.74m
- Incorporated2015
- Employees118.00
- LocationImmunome Inc18702 N. CREEK PARKWAY, SUITE 100BOTHELL 98011United StatesUSA
- Phone+1 (610) 321-3700
- Fax+1 (302) 655-5049
- Websitehttps://immunome.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.20bn | 51.00 | -- | 3.82 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.26bn | 125.00 | -- | 5.96 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.34bn | 287.00 | -- | 16.47 | -- | 21.41 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.39bn | 619.00 | -- | 10.92 | -- | 8.63 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.45bn | 627.00 | -- | 4.90 | -- | 10.22 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.48bn | 118.00 | -- | 7.80 | -- | 255.80 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.59bn | 240.00 | -- | 3.30 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.70bn | 95.00 | -- | 7.04 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 2.70bn | 84.00 | -- | 4.37 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.73bn | 483.00 | -- | 2.83 | -- | 49.06 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.74bn | 385.00 | -- | 37.21 | -- | 6.28 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.74bn | 143.00 | -- | 7.53 | -- | 38.76 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.76bn | 131.00 | -- | 2.53 | -- | 12.86 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.78bn | 824.00 | 92.72 | 2.21 | 52.74 | 5.61 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
Data as of Feb 13 2026. Currency figures normalised to Immunome Inc's reporting currency: US Dollar USD
52.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 13.06m | 11.83% |
| T. Rowe Price Investment Management, Inc.as of 31 Oct 2025 | 10.64m | 9.65% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 5.24m | 4.75% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.21m | 4.73% |
| Redmile Group LLCas of 30 Sep 2025 | 5.02m | 4.55% |
| Point72 Asset Management LPas of 30 Sep 2025 | 4.82m | 4.37% |
| EcoR1 Capital, LLCas of 30 Sep 2025 | 4.08m | 3.70% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 3.65m | 3.31% |
| Opaleye Management, Inc.as of 30 Sep 2025 | 3.19m | 2.89% |
| PRIMECAP Management Co.as of 30 Sep 2025 | 3.02m | 2.74% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
